Scholarlink

Purpose of review: <p>To summarize contemporary evidence regarding procedural and major surgical interventions for interstitial cystitis/bladder pain syndrome (IC/BPS), with emphasis on patient selection, clinical outcomes, durability, and morbidity in patients with refractory bladder-centric disease.</p> Recent findings: <p>Less invasive procedural therapies including hydrodistension, Hunner lesion fulguration, intradetrusor botulinum toxin A injection, and neuromodulation demonstrate variable but often meaningful short-term symptom improvement, though recurrence and repeat intervention are common. Contemporary series evaluating supratrigonal cystectomy with augmentation cystoplasty and urinary diversion report substantial reductions in pain and improvements in functional bladder capacity in carefully selected patients. However, these benefits are accompanied by significant perioperative complication rates, long-term morbidity, catheter dependence, and risk of persistent or recurrent symptoms.</p> Summary: <p>Surgical management of IC/BPS remains symptom-directed rather than curative. While selected patients with clearly bladder-centric, refractory disease may achieve meaningful improvement following major reconstructive or extirpative surgery; morbidity is considerable, and comparative evidence remains limited. Future prospective studies incorporating standardized pain and quality-of-life metrics are needed to refine surgical sequencing and optimize patient selection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Comprehensive Review of Surgical Interventions for Interstitial Cystitis/Bladder Pain Syndrome

  • 期刊论文

  • 发表日期：

    2026年5月21日

查看全文
  • Hailey Travis,
  • Eric Seeger,
  • Rosalie Zurlo,
  • Vinita Gottipati,
  • Elise J.B. De,
  • Brian M. Inouye

摘要

Purpose of review:

To summarize contemporary evidence regarding procedural and major surgical interventions for interstitial cystitis/bladder pain syndrome (IC/BPS), with emphasis on patient selection, clinical outcomes, durability, and morbidity in patients with refractory bladder-centric disease.

Recent findings:

Less invasive procedural therapies including hydrodistension, Hunner lesion fulguration, intradetrusor botulinum toxin A injection, and neuromodulation demonstrate variable but often meaningful short-term symptom improvement, though recurrence and repeat intervention are common. Contemporary series evaluating supratrigonal cystectomy with augmentation cystoplasty and urinary diversion report substantial reductions in pain and improvements in functional bladder capacity in carefully selected patients. However, these benefits are accompanied by significant perioperative complication rates, long-term morbidity, catheter dependence, and risk of persistent or recurrent symptoms.

Summary:

Surgical management of IC/BPS remains symptom-directed rather than curative. While selected patients with clearly bladder-centric, refractory disease may achieve meaningful improvement following major reconstructive or extirpative surgery; morbidity is considerable, and comparative evidence remains limited. Future prospective studies incorporating standardized pain and quality-of-life metrics are needed to refine surgical sequencing and optimize patient selection.